The Myasthenia Gravis Impairment Index was developed to incorporate patient input at different stages of disease progression.
Treatment with eculizumab was associated with a significant benefit on quality of life.
The FDA has approved Soliris for treating adults with myasthenia gravis.
Patients with anti-muscle-specific kinase myasthenia gravis typically have a more severe disease presentation, with early bulbar, neck, and respiratory muscle weakness.
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Sixty-three percent of patients achieved a complete and stable response that allowed them to discontinue all immunotherapies.
Patients who underwent surgery also experienced lower distress levels from treatment-related symptoms.
The guidelines are the result of a consensus of an international task force of MG experts.
Treatment has been linked to durable, symptom-free, treatment-free remission in several cases of MG.
Neurology Advisor Articles
- Updated Ischemic Stroke Guidelines: Expert Takeaways
- Alternative Genetic Risk Variant for Alzheimer Disease Identified
- Advance Directives for Dementia: Honoring Patient Wishes When You Don't Know What They Are
- Ethical Considerations in New Coma Research
- Poor Sleep Associated With Worse PTSD, Chronic Pain in Youth
- Comparing Reference Points for Deep Brain Stimulation Location in Parkinson Disease
- FDA Approves Clinical Decision Support Tool for Stroke
- US Will Produce Radioisotope for MRI, FDA Says
- Cognitive Decline in Men Linked to Low Serum Sodium
- Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease